ERS Genomics licenses CRISPR gene editing technology to Otsuka Pharmaceutical

Eric Rhodes, CEO of ERS Genomics

Licence to Nobel prize winning CRISPR technology supports internal research and development.

DUBLIN, Ireland, 03 March 2021: ERS Genomics Limited, which was formed to provide broad access to foundational CRISPR/Cas9 intellectual property today announced the signing of a licence agreement with Otsuka Pharmaceutical Co. Ltd. The licence grants Otsuka access to CRISPR/Cas9 genome editing technology for its internal research and development initiatives to address areas of unmet medical need.

ERS Genomics holds an exclusive worldwide licence from co-founder and recent Nobel prize winner Dr Emmannuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.

Eric Rhodes, CEO of ERS Genomics, said: “We are extremely pleased to be able to provide Otsuka with access to the CRISPR/Cas9 licence. We hope this brings significant value to Otsuka as it applies the technology to its internal programmes.”

Financial details of the agreement are not disclosed.

Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo Corporation, serves as the exclusive agent for ERS Genomics in Japan.

To read more information, click here.

Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value and generate interest from commercial leads, investors and partners.

Zyme Communications